The FDA expanded the indication for olopatadine hydrochloride and mometasone furoate nasal spray to include children aged 6 to younger than 12 years with seasonal allergic rhinitis. Approval was supported by a phase 3 trial demonstrating improved nasal symptoms versus placebo.

Pediatric hearing loss care has shifted from physiologic detection and rehabilitation toward genetic diagnosis, prognostic counseling, and emerging targeted therapies. Advances in screening, cochlear implantation, and genetic testing have expanded etiologic evaluation, while therapeutic applications remain in early development.

The American Thoracic Society updated guidance for childhood interstitial lung disease in infants, emphasizing genetic testing, chest imaging, biopsy indications, and transplant referral. Recommendations formalize evaluation priorities for rare pediatric lung disorders.

A retrospective study of 606 pediatric patients found serum specific IgE testing for allergic rhinitis was frequently negative in children younger than 3 years and became more informative with age. Findings may aid diagnostic decision-making, though prospective validation is needed.

Natural language processing models analyzing speech from children ages 9 to 13 predicted future mental health conditions more accurately than expert-rated stress assessments. Findings suggest linguistic patterns may serve as an early risk signal, though validation in larger cohorts is still needed.

ACOG has revised its approach to postmenopausal bleeding evaluation, recommending combined transvaginal ultrasonography and endometrial sampling for most patients at initial presentation. The update reflects rising endometrial cancer incidence, evolving evidence on cancer subtypes, and recognized limitations of ultrasound-only evaluation.